Infinity Signs Master Clinical Supply Agreement With Roche - Quick Facts

(RTTNews) - Infinity Pharmaceuticals, Inc. (INFI) has reached a master clinical supply agreement with Roche under which Roche will supply Gazyva to Infinity for use in planned clinical studies to assess the combination of Gazyva and duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase or PI3K delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers.

Also, the companies have entered into a material transfer agreement, pursuant to which Infinity is supplying Roche with duvelisib for use in Roche's preclinical and translational research to evaluate the combination of duvelisib and Gazyva.

Infinity plans to begin a Phase 1b/2 study of duvelisib in combination with Gazyva or rituximab in patients with previously untreated indolent non-Hodgkin lymphoma or iNHL in 2014. Also, it expects to initiate in 2014 a Phase 1b study of duvelisib in combination with Gazyva in patients with chronic lymphocytic leukemia, whose disease has progressed following treatment with a Bruton's tyrosine kinase or BTK inhibitor.

In addition, Roche plans to study duvelisib as part of its preclinical and translational efforts in hematology. These research efforts would be part of Roche's ongoing efforts to further understand the therapeutic potential of Gazyva in combination with both approved medicines and experimental therapies.